News

The approved label changes are limited to revisions pertaining to the product’s storage, instructions of use and use in special populations, and do not impact its indication. "We’re

The new dosage strengths are 8.6 mg/2.1 mg and 11.4 mg/2.9 mg buprenorphine/naloxone CIII sublingual tablets. The 8.6 mg/2.1 mg dosage strength is expected to be launched early

This is Mettrum’s second license under the MMPR. The license authorizes Agripharm to grow 9,000 marihuana plants at its facility located on 80 acres of appropriately-zoned land in

The trial met its primary endpoint by demonstrating that treatment with 5 mg of CCX140 given orally once daily added to a standard of care regimen (SOC) of

Patient enrollment in the Phase II clinical trial will be initiated as soon as possible, according to the company. AC-201 has shown the ability to inhibit the production

The license agreement replaces the prior development and collaboration agreement, under which the two firms were jointly developing ONT-380. Under the license deal, Oncothyreon will pay Array $20m

For three years, the vaccine has been available in trivalent formulation and now it is available in a quadrivalent formulation to help protect against four strains of influenza

The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have also granted orphan drug designation for selinexor to treat patients with DLBCL. The Phase IIb

The US FDA has also granted fast track designation to defibrotide for the treatment of severe VOD. In its severe form, VOD can be life-threatening and is related